BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.3%

Neg 0% Neu 87.3% Pos 0%

BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.

Comments

No comments yet. Be the first!